



UNITED STATES PATENT AND TRADEMARK OFFICE

DEC 28 2009

Commissioner for Patents  
United States Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

Office of Regulatory Policy  
Food and Drug Administration  
10903 New Hampshire Ave., Bldg. 51, Rm. 6222  
Silver Spring, MD 20993-0002

Attention: Beverly Friedman

Dear Ms. Axelrad:

Transmitted herewith is a copy of the application for patent term extension of U.S. Patent No. 7,060,250. The application was filed on February 2, 2009, under 35 U.S.C. § 156. It is noted that applicant also filed an application for patent term extension for NDA 21-711 in U.S. Patent No. 6,676,929 (FDA-2009-E-0165), pursuant to 37 CFR 1.785.

The patent claims a product that was subject to regulatory review under the Federal Food, Drug and Cosmetic Act. Subject to final review, the subject patent is considered to be eligible for patent term extension. Thus, a determination by your office of the applicable regulatory review period is necessary. Accordingly, notice and a copy of the application are provided pursuant to 35 U.S.C. § 156(d)(2)(A).

Inquiries regarding this communication should be directed to Raul Tamayo at (571) 272-7728 (telephone) or (571) 273-7728 (facsimile).

Mary C. Till  
Legal Advisor  
Office of Patent Legal Administration  
Office of the Associate Commissioner  
for Patent Examination Policy

cc: Terry Mahn  
Fish & Richardson P.C.  
1425 K Street, N.W.  
11th Floor  
Washington, D.C. 20005

RE: VASOVIST® (gadofosveset trisodium)  
Docket No.: FDA-2009-E-0169